$LIVN

LivaNova PLC (LIVN): Submission of Matters to a Vote of Security Holders

LivaNova PLC (LIVN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. livn-20260610 0001639691 false 0001639691 2026-06-10 2026-06-10 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):

Original reporting
Published Jun 11, 2026, 1:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 11, 2026, 1:09 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$LIVN
Neutral
high confidence
Mentioned
$LIVN
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$LIVNNeutralLow
01

Why it matters

Confirms governance and capital-authority resolutions (board elections, advisory Say-on-Pay, PwC-U.S. as auditor, and renewed share allotment/equity issuance powers). No new business or financial guidance is provided.

02

Market read

Primarily a procedural governance/corporate-authority update; limited direct trading catalyst absent any announced financing or strategic transaction.

03

What to watch

The only potentially tradable element is the renewed authority to allot shares/equity for cash up to a stated nominal amount; however, the filing does not announce an actual issuance.

Relevance 6/10Novelty 3/10Timing: Filed June 11, 2026 for AGM held June 10, 2026.

Background

The company’s 8-K reports the results of its June 10, 2026 Annual General Meeting, referencing a definitive proxy statement dated April 29, 2026.

Company-level read

Ticker impact

$LIVNNeutralHigh confidence
Context

LivaNova filed an 8-K confirming all 10 AGM resolutions were adopted, including director elections, Say-on-Pay, and auditor ratification.

Expected impact

Low near-term impact; any reaction is likely limited to governance/financing overhang expectations rather than fundamentals.

Evidence & confidence

The filing discloses vote tallies and adoption of standard resolutions; it does not introduce new financial guidance, litigation outcomes, or material transactions.

Market effects

Minimal; governance vote outcomes typically do not reset sector risk premia.

Minimal; US-listed filing for a UK-incorporated issuer.

Minimal; no cross-border deal/regulatory action disclosed.

Counterpoint

If traders were positioned around potential board/compensation controversy, the “all resolutions adopted” outcome could reduce tail-risk, but the article provides no evidence of controversy.

Key entities

  • LivaNova PLC

    NASDAQ-listed company whose AGM resolutions were reported via SEC Form 8-K.

  • PricewaterhouseCoopers LLP (PwC-U.S.)

    Ratified as independent registered public accounting firm for 2026.

Related articles

$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

$LIVNHighAI 9/10

LivaNova Q2 Earnings Call Highlights

LivaNova (NASDAQ:LIVN) reported Q2 call updates on oxygenator output, citing manufacturing improvements and better third-party component availability, plus a long-term supply agreement with Thermo Fisher Scientific to ease a component constraint. The company raised 2026 cardiopulmonary revenue growth to 9.5% to 10.5% and epilepsy growth to 7% to 8%. Adjusted gross margin was 71% and adjusted diluted EPS guidance was raised to $4.30 to $4.40.

$LIVNHighAI 9/10

LivaNova PLC: LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance

LivaNova PLC (Nasdaq: LIVN) reported Q2 2026 revenue of $390.6M, up 10.8% reported and 9.8% constant currency. Adjusted diluted EPS was $1.26. It raised full-year 2026 revenue guidance to 8% to 9% constant currency and adjusted diluted EPS to $4.30 to $4.40. It also signed a long-term supply agreement with Thermo Fisher for oxygenator components.

$LIVNHighAI 9/10

Why is LivaNova stock climbing today?

LivaNova shares rose 1.3% in after-hours to $86.42 after the company reported Q2 2026 results. Adjusted EPS was $1.26 vs $1.09 expected, and revenue was $390.6M vs $380.57M. LivaNova raised full-year 2026 adjusted diluted EPS guidance to $4.30-$4.40 (midpoint $4.35). KeyBanc lifted its price target to $92 from $83.

$LIVNHigh

LivaNova PLC (LIVN): Results of Operations and Financial Condition

LivaNova PLC (LIVN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2q2026earningspressrelease.htm EX-99.1 Document EXHIBIT 99.1 NEWS RELEASE LivaNova Reports Second-Quarter 2026 Results; Raises Full-Year 2026 Revenue and Adjusted Diluted EPS Guidance – Delivered double-digit reported revenue growth of 10.8%, with constant-currency rev

$ITWMed

Illinois Tool Works Authorizes $6 Bln Buyback

Illinois Tool Works (ITW) said its board authorized a new share repurchase program of up to $6 billion. The board also approved a 7% increase in its regular annual cash dividend to $6.88 per share, effective with the Q4 dividend of $1.72 payable Oct. 9, 2026. ITW closed at $296.66 on Friday.